The Technical Analyst
Oncotelic Therapeutics, [OTLC]
Exchange: OTC Sector: Healthcare Industry: Biotechnology
Oncotelic Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.82% $0.0394
America/New_York / 3 mai 2024 @ 14:37
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 15.75 mill |
| EPS: | -0.0200 |
| P/E: | -1.970 |
| Earnings Date: | May 17, 2024 |
| SharesOutstanding: | 399.68 mill |
| Avg Daily Volume: | 0.0734 mill |
| RATING 2024-05-03 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.970 | sector: PE 29.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -1.970 | industry: PE 136.10 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.0321 (-181.53%) $-0.0715 |
| Date: 2024-05-06 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0364 - 0.0424 ( +/- 7.61%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-06-29 | Trieu Vuong | Buy | 425 000 | Common Stock |
| 2023-06-28 | Trieu Vuong | Buy | 75 000 | Common Stock |
| 2023-06-16 | Trieu Vuong | Buy | 100 000 | Common Stock |
| 2023-06-14 | Trieu Vuong | Buy | 400 000 | Common Stock |
| 2023-05-26 | Trieu Vuong | Buy | 126 888 | Common Stock |
| INSIDER POWER |
|---|
| 100.00 |
| Last 94 transactions |
| Buy: 129 604 070 | Sell: 133 128 556 |
Forecast:
16:00 - $0.0394
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.0394 (2.82% ) |
| Volume | 0.0213 mill |
| Avg. Vol. | 0.0734 mill |
| % of Avg. Vol | 29.02 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For OTLC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
OTLC
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.
Latest Press Releases
2024-04-29 07:00:00 - Press Release
Mosaic Immunoengineering Agrees To Acquire Clinical Necroptosis Cancer Therapy Assets From Oncotelic Therapeutics, Inc.
- the clinical assets to be acquired include cancer and ocular disease programs, including regulatory and clinical packages and access to oncotelic's ai platform for identifying immunotherapy combinations huntington beach, ca / accesswire / april 29, 2024 / mosaic immunoengineering, inc. ("mosaic" or the "company"), (otc pink:cpmv), a development-stage biotechnology company focused on the development of novel immunotherapies to treat and prevent cancer, today announced the signing of a binding term-sheet with oncotelic therapeutics, inc. (otcqb:otlc) ("oncotelic"), under which mosaic intends to acquire rights to certain of oncotelic's clinical stage necroptosis cancer therapies associated with oncotelic's vascular disruptive agents ("vdas")...
2024-03-25 08:10:00 - Press Release
Linkage Of Cancer And Lupus In Gliomas Patients
Agoura hills, calif., march 25, 2024 (globe newswire) -- oncotelic therapeutics, inc (otcqb:otlc) announced today the peer reviewed publication of transforming growth factor beta 2 (tgfb2) mrna levels, in conjunction with interferon-gamma receptor activation of interferon regulatory factor 5 (irf5) and expression of cd276/b7-h3, are therapeutically targetable negative prognostic markers in low-grade gliomas: past, present, and future strategies in the treatment and management of gliomas.
2024-03-04 08:17:00 - Press Release
Invitation To Participate In Stop-pc Clinical Trial
Agoura hills, calif., march 04, 2024 (globe newswire) -- oncotelic therapeutics, inc (otcqb:otlc) invites participation in our stop-pc clinical trial which is now open for recruitment. additional information can be obtained at www.stop-pc.com. an explainer video is available at https://www.youtube.com/watch?v=c4zse3fuliu.
2024-01-16 08:00:00 - Press Release
Oncotelic Therapeutics Announces Clinical Linkage Of Tgfb2 And Ifngr2 In Pediatric Dmg Patients
Agoura hills, calif., jan. 16, 2024 (globe newswire) -- oncotelic therapeutics, inc (otcqb:otlc) announced today the peer reviewed publication of transforming growth factor beta 2 (tgfb2) and interferon gamma receptor 2 (ifngr2) mrna levels in the brainstem tumor microenvironment (tme) significantly impact overall survival in pediatric dmg patients in the special issue gliomas: signaling pathways, molecular mechanisms and therapeutic approaches.
2023-12-18 08:10:00 - Press Release
Oncotelic Therapeutics Announces Opening Of Gmp Manufacturing Plant
Agoura hills, calif., dec. 18, 2023 (globe newswire) -- oncotelic therapeutics, inc (otcqb:otlc) ("oncotelic", the "company" or "we" or “our”), unveils a state-of-the-art gmp manufacturing plant, a significant stride in biopharmaceutical innovation, through its joint venture sapu biosciences llc. situated in san diego biotechnology hub, this cutting-edge, ai-driven facility marks a pivotal expansion in the company's clinical pipeline, advancing beyond its ot-101 development. discover more at https://sapubio.com/contact/."
Latest News
2022-03-10 08:05:00 - GlobeNewsWire
Oncotelic to Present New Studies on its TGF-β Program at the American Association for Cancer Research (AACR) Annual Meeting 2022
AGOURA HILLS, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“ Oncotelic ” or the “Company”) ( OTCQB:OTLC ), a leading developer of TGF-β therapeutics for oncology and virology, today announced that it will present new studies on its TGF- β program at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13 in New Orleans, Louisiana.
2022-02-24 08:47:00 - GlobeNewsWire
Oncotelic Presenting at MedInvest Pharmaceutical and Biotechnology Investor Conference
AGOURA HILLS, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ( “ Oncotelic ” or the “ Company ” ) ( OTCQB:OTLC ) , a leading developer of TGF-β therapeutics for oncology and virology, today announced that Dr. Vuong Trieu, Oncotelic Chairman and CEO, will be presenting at MedInvest Pharmaceutical and Biotechnology Investor Conference (the “Conference”), from March 28 - April 1, 2022.